Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
2014 · The Lancet · 4,585 citations
https://doi.org/10.1016/s0140-6736(13)62422-8
K
Keyur Mehta
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
51
Papers
13.7K
Citations
28
h-index
34
i10-index
Keyur Mehta is an academic researcher from German Breast group. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology. The author has an h-index of 28, co-authored 44 publications.
Papers by this author
worksDefinition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 · Journal of Clinical Oncology · 2,602 citations
https://doi.org/10.1200/jco.2011.38.8595
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
2014 · The Lancet Oncology · 1,014 citations
https://doi.org/10.1016/s1470-2045(14)70160-3
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
2010 · Journal of Clinical Oncology · 550 citations
https://doi.org/10.1200/jco.2009.23.8451
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
2011 · Journal of Clinical Oncology · 511 citations
https://doi.org/10.1200/jco.2010.31.4930
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
2013 · Journal of Clinical Oncology · 419 citations
https://doi.org/10.1200/jco.2012.45.0940
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat